The pharmacokinetic parameters of luteolin and its glucuronide/sulfate conjugates were studied in rats after a single 50 mg/kg dose of luteolin administered as intravenous bolus or oral solution. Plasma and urine samples were enzymatically hydrolyzed to determine conjugate concentrations of luteolin. Noncompartmental analysis revealed a half-life of 8.94 h for free (unconjugated) and 4.98 h for conjugated luteolin following intravenous administration. Following oral administration, plasma concentrations of luteolin attained a maximum level of 5.5 μg/mL at 5 min and decreased to below LOQ (100 ng/mL) after 1 h. K e could not be calculated because the elimination phase was below LOQ. The low bioavailability (F) of luteolin, 4.10% at a dose of 50 mg/kg, is presumably due to the significant first pass effect. For i.v. administration, the maximum concentration of luteolin was 23.4 μg/mL at 0 h. The plasma concentration versus time profile of luteolin was biphasic, subdivided into a distribution phase and a slow elimination phase for oral and intravenous administration. Luteolin was found to have a large volume of distribution and a high clearance. Double peaks were found after intravenous and oral administration, suggesting enterohepatic recirculation.
Flavonoids are polyphenolic compounds widely distributed in plants and vegetables. They have been reported to possess numerous biological effects such as antioxidant, free-radical scavenger, antiinflammatory, antiestrogenic, and antiproliferative activities [1, 2] . These effects are helpful for human health, such as in the treatment and prevention of cancer, cardiovascular disease, and other pathologies [1, 2] . The flavone luteolin usually occurs in its glycosylated forms in celery, green pepper, camomile tea, and artichoke. It has been reported to have antitumorigenic [3, 4] , anticancer [5] [6] [7] [8] , antiproliferative [9, 10] , and antioxidant effects [6] and has been recognized as an inhibitor of protein kinase C [11] and xanthine oxidase [12, 13] . The absorption and metabolism of luteolin have been evaluated in vitro using Caco-2 cells and microsomes obtained from liver or intestine of rats and humans [14, 15] . In addition, pharmacokinetic studies in animals and humans of luteolin and luteolin-rich plants have been reported [16] [17] [18] [19] . However, until now, in vivo investigations of the disposition, absorption, bioavailability, and metabolism of luteolin are limited. Therefore, in the present experiments, the pharmacokinetics of luteolin and its glucuronide/sulfate conjugates after oral and intravenous (i.v.) injection in rats were determined. In addition, the elimination of luteolin after oral and intravenous administration was measured in urine samples. For the present investigation, we focused on the pharmacokinetic evaluation of the aglycone luteolin because recently we demonstrated that this compound produces strong xanthine oxidase inhibition in vitro [13] .
The concentration-time profiles and the pharmacokinetic parameters of free luteolin after oral and i.v. administration are presented in Table 1 and Figure 1 . The plasma concentration of luteolin attained a maximum level of 5.49 μg/mL 5 min after oral administration of luteolin to rats at a dose of 50 mg/kg. The low bioavailability (F) of luteolin, 4.10% at a dose of 50 mg/kg, is presumably due to the significant first pass effect. Following Table 1 : Pharmacokinetic (PK) parameters of unconjugated luteolin after oral and i.v. administration of luteolin at a dose 50 mg/kg. Table 2 : Pharmacokinetic (PK) parameters of luteolin conjugates after oral and i.v. administration of luteolin at a dose 50 mg/kg. All PK parameters presented in Tables 1 & 2 are mean values calculated by a normalized dose (50 mg/kg). AUC = area under the curve; Cmax = maximal plasma concentration; T max = time to reach C max ; K e = elimination rate constant; t ½ = elimination half life; Cl/F = clearance after oral administration; Cl = clearance; Vd area = distribution volume; AUC 0-last = area under the moment curve extrapolated to T last ; AUC 0-∞ = area under the curve extrapolated to infinity; F = oral bioavailability; ND = not determined i.v. administration, the maximum concentration of luteolin was 23.42 μg/mL at 0 h. The plasma concentration versus time profile of luteolin was biphasic, subdivided into a distribution phase and a slow elimination phase for oral and intravenous administration. The concentration-time profiles and the pharmacokinetic parameters of luteolin conjugates after oral and i.v. administration are presented in Table 2 and Figure 1 . Plasma concentrations of luteolin conjugates after oral and i.v. administration of luteolin attained maximum levels of 5.77 μg/mL at 0.25 h and 4.31 μg/mL at 0.08 h, respectively, and decreased to below the LOQ at 24 h. However, the half-life for luteolin was greater than that of conjugated luteolin following i.v. injection. Double peaks were found for luteolin conjugates after oral and i.v. administration at 0.25 and 1 h, respectively, suggesting it might pass enterohepatic circulation.
Urinary excretion of free luteolin and its conjugates within 24 h after oral and intravenous administration of luteolin was very low (0.98 -4.97% of the dose), which suggests that these compounds are not primarily excreted via the urine (Table 3 ). Data expressed as mean ± SD (n = [8] [9] [10] [11] Free luteolin and luteolin conjugates were present in rat plasma and urine after oral and intravenous administration. However, the conjugates (glucuronides or sulfates) could not be further identified in this study since the analytical method was developed only for the parent compound. The presence of free luteolin suggested that some of it can escape intestinal and hepatic conjugation.
The pharmacokinetic profiles of free luteolin and luteolin conjugates in rat plasma are presented in Figure 1 . When luteolin was administered orally, the maximum concentrations of luteolin and luteolin conjugates were 5.49 and 5.77 μg/mL at 5 min and 15 min, respectively. The total concentration of luteolin in rat plasma 5 min after dosing was 9.25μg/mL. Shimoi et al. [18] dose of a Chrysanthemum morifolium extract (102 mg/kg containing 7.60% luteolin, 7.75 mg/kg luteolin) [16] . In humans, peak plasma concentrations of total luteolin were reached within 0.5 h with a maximum level of 156.5 ± 92.29 ng/mL after a single oral dose of an artichoke leaf extract (153.8 mg containing luteolin-7-O-glucosides; equivalent to 35.2 mg luteolin) [19] . The differences observed in these studies could be explained by the initial dose administration, the solvents used to dissolve luteolin and the source of intake flavonoids (extract versus pure compound). Figure 2 illustrates the fitted luteolin concentrations versus time profiles with the two compartment body model. It can be seen that the model describes the luteolin data very well. The AIC and SC were -11.18 and -9.59, representing a good fit. The PK parameters obtained by fitting the mean concentrations versus time profiles of luteolin concentrations after i.v. treatment are presented in Table 4 .
The rapid absorption of several flavonoids has been reported in previous literature. For example, in humans, the main peak appeared approximately 2.9 h after quercetin administration [20, 21] . In rats, flavonoids seem to appear more rapidly. When luteolin was administered via gastric intubation, the compound was detected in rat plasma after 15 min [18] , whereas quercetin (given orally) appeared after 5 min [22] . Apigenin given intraperitoneally, appeared in plasma after 30 min [23] . Based on these literature data, the presence of flavonoids in the blood occurs within a few minutes to a few hours, which correlates with our results.
The low bioavailability of luteolin (F = 4.1%) and the high metabolite concentrations indicate a first pass metabolism. Absorbed luteolin undergoes biotransformation (methylation, glucuronidation or sulfation), as has been shown in previous studies. For example, in vitro experiments demonstrated that 74% of luteolin was conjugated to glucuronic acid after incubation with microsomal samples from the human intestine [14] . The most common binding sites of the molecule were the hydroxyl groups in the 3′-and 4′-position (51% and 44%) [14] . Boersma et al. [14] found three glucuronosyl conjugates of luteolin, 7-O-, 3′-O-and 4′-O-glucuronosyl luteolin, after incubation with microsomes from rats and humans.
Shimoi et al. [18] investigated the absorption of luteolin by rat inverted small intestine. Luteolin was recovered in rat plasma as two metabolites, the glucuronidate or sulfate forms of the O-methylate conjugate. Only a small part of the compound remained unconjugated. Murota et al. [15] reported the uptake and transport of flavonoid aglycones by human intestinal Caco-2 cells. The flavonoids quercetin, kaempferol, luteolin and apigenin were converted to their glucuronide/sulfates by Caco-2 cells, and the level of the intact aglycone was lower than those of the glucuronide/sulfates in the basolateral solution.
In addition to the first-pass metabolism, the role of efflux transporters in contributing to the low oral bioavailability of drugs has been well acknowledged [24] . Among the efflux transporters located in the intestine and the liver, the ATP-binding cassette (ABC) superfamily, including several members such as P-glycoprotein (P-gp), multidrug resistance associated proteins (MRPs), and breast cancer resistance protein (BCRP/MXR), has been well investigated for its roles in intestinal and hepatic disposition of drugs [24] . Increasing evidence has demonstrated the interactions of flavonoid aglycons and glycosides with ABC transporters. For example, ginkgo flavonols, quercetin, kaempferol, and isorhamnetin were demonstrated to be the substrates of P-gp in the Bacap37/MDR1 transfected cell model [25] . The interaction of flavonoid aglycones and glycosides with ABC transporters may greatly influence their absorption, disposition and excretion in the body, and also alter pharmacokinetic profiles of the concurrently administrated drugs acting on the same transporters, thereby probably leading to significant impacts in the therapeutic outcomes.
However, the bioavailability of luteolin is similar to that of quercetin [15] . Chen et al. [22] reported the systemic bioavailability of quercetin and quercetin conjugates as 5.3% and 55.8%, respectively, in rats. Moreover, after oral administration of quercetin, about 93.3% of it was metabolized in the gut, with only 3.1% metabolized in the liver. Interestingly, the half-life for free luteolin was greater than that for conjugated luteolin following i.v. injection. This is unusual since in theory the metabolites should not have a shorter half-life than the parent drug. However, similar results were reported by Cave et al. [26] , who also reported a longer half-life for the parent compound genistein than for the genistein metabolites after i.v. injection.
Therefore, the pharmacokinetic variables reported for the conjugates should be interpreted with caution, since they describe the appearance and disposition of endogenously synthesized compounds, each of which may possess distinct kinetics [26] . It also can be suggested that the terminal half-life has not been reached yet and that by using a more sensitive assay one would find a little longer half-life of the conjugates. Thus, a more complete analysis of the metabolism of luteolin will require separation into individual metabolites and kinetic analysis of the individual compounds.
Only small amounts of free luteolin and luteolin conjugates were found to be eliminated in the urine in our study. This is consistent with the observations by others. Shimoi et al. [18] reported an excretory recovery of unmodified luteolin in rat urine of 4%. Luteolin conjugates were recovered only by 1.99 ± 1.50% after intake of luteolin-7-O-glucoside [19] . Comparably, only 0.58% of apigenin was recovered in urine samples within 24 h after parsley ingestion in humans [27] . Gugler et al. [28] found that after intravenous administration of quercetin (100 mg), 7.4% of the dose was excreted in the urine as a conjugated metabolite and 0.65% of the dose was recovered in the form of unchanged quercetin.
Therefore, it seems that the urinary elimination of luteolin is not the main excretion route in rats. At present, it can be speculated that excretion via feces may be the main route of elimination of luteolin and, in particular, its metabolites [29] .
Since in the present study multiple peaks were detected in the plasma after oral and intravenous [31] reported an enterohepatic recirculation of naringenin in rat plasma. However, our data did not show multiple peaks in the plasma concentration-time profile of free luteolin after intravenous and oral administration, presumably due to the limited number of data time points.
In conclusion, after oral administration of luteolin, the compound was rapidly absorbed and metabolized in plasma. Moreover, plasma-concentration-time curves of luteolin metabolites revealed secondary peaks. The bioavailability of luteolin was low and the urinary excretion of luteolin and its conjugates did not dominate. Further studies are needed to confirm that the luteolin C max and AUC data reported here are genuinely associated with the threshold of its reported antitumorgenic, antiproliferative and xanthine oxidase inhibitory effects. In addition, 
Animals:
Male Sprague-Dawley rats, weighing 300-400 g were purchased from Harlan (IN, USA) and divided into the experimental groups, each containing 8-11 rats. The animals were housed in plastic cages and were allowed to adapt to their environment for one week before used for experiments. All the animals were maintained on a 12h/12h light/dark cycle. They received a standard chow and water ad libitum during the duration of the experiment. All animal experiments were performed according to the policies and guidelines of the Institutional Animal Care and Use Committee (IACUC) of the University of Florida, Gainesville, USA (NIH publication # 85-23).
Methods:
The pharmacokinetic studies were carried out by the sparse sampling approach wherein blood samples were collected from 8-11 rats. Luteolin was administered to two groups of rats (n = 8-11 in each group). Group one received a single i.v. dose of 50 mg/kg of luteolin via the tail vein. Group two received the same dose orally by gavage. Luteolin was dissolved in 30% DMSO and 70% polyethylenglycol (PEG) 200. Plasma samples (250 μL per blood sample) were collected from the sublingual vein into heparinized tubes at 3, 5, 10, 30 min, and 1, 2, 4, 6, 12 , and 24 h for i.v. injection, and at 5, 10, 15, 30, 45 min, and 1, 2, 4, 6, 12, and 24 h for oral administration. Prior to blood collection, the rats were anaesthetized with halothane and the blood loss was replaced with an equal volume of isotonic saline. The blood sample was centrifuged for 15 min at 4,000 rpm at 4 o C. The supernatant, in aliquots of 0.20 mL, was transferred into tubes and 10 μL of 0.58 M acetic acid was added to each aliquot for stabilization. The plasma samples were stored at -80 o C until analysis. Urine was collected over 24 h and an aliquot of 50 mL was mixed with 1 g ascorbic acid as antioxidant and stored at -80 o C until analysis.
Analytical methods:
The plasma concentrations of unchanged free and conjugated luteolin in rat plasma and urine were determined by the method published earlier, with slight modifications [19] . Plasma and urine samples were analyzed using a Shimadzu VP series HPLC system (Kyoto, Japan) equipped with an SPD-M10Avp diode array detector. A Lichrospher® 100 RP-18 (5 μm. Merck KgaA) was used for the separation of luteolin. The column was kept at 25 o C. The eluents were (A) 50 mM phosphate buffer (NaH 2 PO 4 , pH 2.1) and (B) CH 3 CN. The following solvent gradient was applied: 20% B (6 min) and 20-50% B (21 min).The gradient was followed by 10 min column flushing and post-run equilibration, respectively. Total run time was 40 min. The flow rate was 1 mL/min. Forty μL of each sample was injected into the RP-HPLC system. Chromatograms were acquired at 330 nm. For the determination of total luteolin, 10.0 μL internal standard (naringenin, 1.05 mg/mL), 10.0 μL 0.5% (m/v) ascorbic acid and 20.0 μL acetic acid (0.58 M) were added to 200.0 μL of the plasma sample, followed by the addition of 12.0 μL β-glucuronidase/sulfatase solution. The mixture was incubated at 37 o C for 1 h. Protein was precipitated by adding 240 μL of acetone. The mixture was vortexed for 1 min and centrifuged for 15 min at 4000 rpm at 4 o C. The supernatant was transferred to tubes containing 4.0 μL 0.5% (w/v) ascorbic acid and 8.0 μL 1 M trifluoroacetic acid, and evaporated to dryness in a vacuum centrifuge. The residue was reconstituted in 60 μL of methanol: water (1:1, v/v), centrifuged for 10 min at 13,200 rpm, and 40 μL was injected into the HPLC. For the determination of unchanged luteolin in plasma, the sample was extracted in the same manner as described above, without adding the enzyme. The concentrations of luteolin and its conjugates in urine samples were measured using the same method as described for the plasma, except urine samples were centrifuged for 15 min at 13,200 rpm after adding 240.0 μL acetone, and then 40.0 μL of the supernatant was injected into the HPLC.
The conjugates (glucuronides or sulfates) of luteolin were calculated by subtracting total luteolin from unchanged luteolin. The calibration curve was linear in the examined concentration range of 0.1 to 50 μg/mL with (R 2 ≥ 0.99), with the detection limit of 0.1 μg/mL. The inter-day and intra-day precisions were less than 15%. The extraction recoveries were more than 90% for all samples.
Data analysis:
Mean concentration of luteolin and its conjugates versus time curves were generated in Grapad Prim® (version 4.0, San Diego, CA). The pharmacokinetic parameters were determined by noncompartmental and compartmental analysis using WinNonlin software package, version 4.1, (Pharsight Corporation, USA). The mean data were used for the analysis. Non-compartmental PK: The PK parameters determined were the AUC, maximum concentration in plasma (C max ), time to reach C max (T max ), the elimination rate constant (k e ), the elimination half life (t 1/2 ), the volume of distribution (V d ) and the clearance (CL). AUC 0→last was calculated using a linear/log trapezoidal method from time zero to last sampling point equal to or above the lower limit of quantification. Both C max and T max were obtained from the plots of plasma concentration versus time. The k e was obtained by linear regression of the terminal log linear phase of the concentrationtime curve. The elimination half-life (t 1/2 ) was determined as 0.693/k e . The volume of distribution area (Vd area ) was calculated using CL/k e . The clearance (Cl) was calculated as Dose/AUC and the systemic bioavailability (F %) was calculated as F % = (AUC p.o. /AUC i.v.. ) × 100. Compartmental PK: Luteolin concentrations showed a better fit in a two compartment body model compared to a one compartment body model. The equation for the two compartment model (Figure 2 ) is as followed: C = A.e-αt + B.e-βt (i.v.), where C is the concentration of drug in plasma at time t; A and B are the mathematical coefficient; α is the distribution rate constant; β is the elimination rate constant; and t is time. After i.v. administration, AUC 0-∞ was calculated using following equation: AUC 0-∞ i.v. = A/α + B/β. The elimination half life was calculated as ln (2/k e ). The volume of distribution of central compartment (Vc) was calculated as Dose/Ke × AUC. The volume of distribution of peripheral compartment (Vt) was calculated as Vc × k12/k21. The clearance (Cl) was calculated as Dose/AUC. Goodness of fit was determined by the AIC (Akaike Criteria) and SC (Schwartz Criteria). The lower the AIC and SC, the more appropriate is the selected model.
Validation:
The method was validated over the range of concentration of luteolin present in plasma and urine. The validation parameters of linearity, sensitivity, specificity, precision, accuracy and stability were determined. Plasma: The calibration curve (n = 9) operating in the range of 100-10000 ng/mL for luteolin in rat plasma was linear (r 2 > 0.99). The limit of quantification (LOQ) of luteolin in plasma was 100 ng/mL. The precisions intra-and inter-day for luteolin were satisfactory with CV values between 1.3 and 12.3%. Similarly, the accuracy of the assay obtained with quality control samples containing 300, 800, and 3000 ng/mL luteolin was between 94.2 and 106.3% of the nominal values. The mean recovery assessed at three distinct levels of concentration (100, 500 and 10000 ng/mL) ranged from 95.7 to 106.4% of the expected values. Urine: The calibration curve (n = 9) operating in the range of 500-50,000 ng/mL for luteolin in rat urine was linear (r 2 > 0.99). The LOQ of luteolin in urine was 500 ng/mL. The precisions intra-and inter-day for luteolin were satisfactory with CV values between 0.30 and 13.25%. Similarly, the accuracy of the assay obtained with quality control samples containing 500, 3,000, and 10,000 ng/mL luteolin was between 98.21 and 109.28% of the nominal values. The mean recovery assessed at three distinct levels of concentration (500, 3,000 and 10,000 ng/mL) ranged from 99.56 to 112.23% of the expected values.
